[BidClub_]

Investment pitches

sort:
3 loaded
  1. 86

    VRT has recession cushions, but AI concentration leaves downside

    412 wordsEquityX ↗
    • VRT’s recession case rests on more cash than debt, roughly $2.5B of guided adjusted FCF, and services/spares representing 20% of revenue on installed equipment.
    • A $15B backlog and $3.6B of customer prepayments provide visibility; in 2020, sales fell only 1.4%, orders grew 9.7%, and backlog reached a record despite a 65% stock crash.
    • At $194, 2027 EPS 30% below the $9.18 consensus implies roughly 30x earnings. The author might start adding slowly, while expecting buyers at that valuation.
    • The main risks are 85% data-center revenue, project timing already causing a missed quarter, and stale backlog data; 2022 showed margins can collapse even as sales grow.
  2. 83

    Lumentum can survive a recession; the stock may not

    381 wordsEquityX ↗
    • LITE has $2.74B cash versus $1.67B debt and roughly 40% adjusted operating margin, giving the author confidence it can survive a recession.
    • AI data-center optics now dominate revenue, with capacity reportedly booked through early 2029; however, hyperscaler capex and customer inventory remain key dependencies.
    • The last optics downturn cut revenue 23%, GAAP gross margin from 46% to below 19%, and the stock 68%; repeating that decline from $1,143 implies roughly $380 versus $756 today.
    • The author is adding now but would scale near $400; at $756, fiscal 2028 EPS 30% below the $35.92 consensus would still imply roughly 30x earnings, leaving room for multiple compression.
  3. 82

    VRT: AI infrastructure growth, but orders need proving

    451 wordsEquityX ↗
    • VRT is 49% below its May high despite Q2 revenue rising 24%, adjusted EPS 60%, and operating margin reaching 22.6%; the author sees AI power and cooling demand as underpriced.
    • Full-year guidance increased to $13.8–14.2B sales and $6.65–6.75 EPS; $925M quarterly free cash flow, net cash, and deferred revenue doubling to $3.6B reinforce execution.
    • Analysts expect 30% 2027 revenue growth; at 21x estimated 2027 EPS of $9.18 and 4.1x sales, the author views valuation as attractive if orders validate it.
    • The author is waiting for Wednesday: a Q3 guide hit plus new orders or backlog could confirm the thesis. Another organic-growth miss or guidance cut would change their mind; hyperscaler capex remains the key dependency.